



UNITED STATES PATENT AND TRADEMARK OFFICE

72
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/754,775

01/04/2001

David J. Grainger

295.009US3

6351

7590

05/04/2006

Rochelle K Seide
Baker Botts LLP
30 Rockerfeller Plaza
New York, NY 10112

EXAMINER

KIM, JENNIFER M

ART UNIT

PAPER NUMBER

1617

DATE MAILED: 05/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/754,775	Applicant(s) GRAINGER ET AL.	
	Examiner Jennifer Kim	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 16 February 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 173-194, 196-203, 205-211 and 231 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 173-194, 196-203, 205-211 and 231 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>2/16/2006</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The response filed February 16, 2006 have been received and entered into the application.

Action Summary

The Double Patenting rejection of claims 173-194, 196-203, 205-211 and 231 provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 153-173 of copending Application No. 10/729,056 is being maintained for the reasons stated in the previous Office Action.

The Double Patenting rejection of claims 173-194, 196-203, 205-211 and 231 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 8 of U.S. Patent No. 6,410,587B1 is being maintained for the reasons stated in the previous Office Action.

The rejection of claims 173-181 and 207-211 under 35 U.S.C. 112, first paragraph is hereby expressly withdrawn in view of Applicant's amendment.

The rejection of claims 173-181, 205-211 and 231 under 35 U.S.C. 103(a) as being unpatentable over Sawada et al. (Pharmacometrics, 1992) is being maintained for the reasons stated in the previous Office Action.

Art Unit: 1617

The rejection of claims 182-194, 196-203, 205, 206 under 35 U.S.C. 103(a) as being unpatentable over Warri (Dissertation Abstracts International, 1993) is being maintained for the reasons stated in the previous Office Action.

Response to Arguments

Applicant's arguments filed February 16, 2006 have been fully considered but they are not persuasive. With respect to Applicant's argument regarding judicially created doctrine of obviousness-type double patenting over claim 8 of U.S. Patent No. 6,410,587 (the '587 patent"), Applicant argues that the claims of the present invention are patentably distinct from claim 8 of the '587 patent, because the compounds encompassed by formula I of the present invention is not same as the compounds encompassed by the formula of claim 8 of the '587 patent because group R3 of formula I of the present invention, which corresponds to group R9 of the formula of claim 8 of '587 patent differ since R3 can be either an ethyl or a chloroethyl, while R9 is a cyclic group of various varieties. This is not persuasive because R3 of formula I of the present invention corresponds to group R7 rather than R9 of the patent '587. R3 in present invention can be ethyl or chloroethyl which corresponds to R7 as being (C1-C12)alkyl. It is clear that the substituents in R3 of ethyl is within the C1-C12 alkyl group of R7. Moreover, the phenyl-ring with Y substituents (wherein Y is H) in the present invention of formula I corresponds to R9 of the patent '587 where in R9 can be (C3-

Art Unit: 1617

C6)cycloalkenyl. Accordingly, the judicially created doctrine of obviousness-type double patenting is deemed proper. With respect to 35 U.S.C. 103(a) rejection over Sawada et al, Applicant argues that there is no sufficient suggestion or motivation to utilize toremifene to treat cardiovascular or vascular indications and therefore a person of ordinary skill in the art would not be motivated to utilize toremifene to treat a cardiovascular or vascular indication characterized by decreases in lumen diameter, based upon the teachings of Sawada. This is not persuasive because Sawada teaches the effect of toremifene possessing lowering cholesterol level. This teaching would motivate one of ordinary skill in the art to employ toremifene for the treatment of conditions related to accumulation of cholesterol or lipid particularly conditions related to cardiovascular indications such as atherosclerosis. Further, once a compound is well known in the art as having pharmaceutical effect it is obvious to generally optimize the effective dosage amounts. With respect to Applicants' argument regarding Warri, Applicant argues a person of ordinary skill in the art would not have a reasonable expectation of success based upon the teachings of Warri because Warri does not teach administration of toremifene to treat cardiovascular or vascular indications characterized by decreased lumen diameter. In response, Applicant's attention is drawn to rejected claims drawn to a therapeutic method of increasing the level of TGF-beta in a mammal in need thereof, comprising administering an effective amount of a compound of formula (I). Warri teaches the administration of toremifene enhancing TGF-beta level in vitro and in vivo in breast cancer and the growth of breast cancer is inhibited by toremifene. Therefore this teaching encompasses and obviate Applicant's

Art Unit: 1617

claimed invention because it would have been obvious to one of ordinary skill in the art to employ toremifene in a mammal to increase the level of TGF-beta in order to achieve an expected benefit of treating breast cancer in mammal in any population including the patients having any other secondary disorders including diabetes, retinopathy.

In view of the above Office Action of August 11, 2005 is deemed proper and asserted with full force and effect herein to obviate applicant's claims.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 173-194, 196-203, 205-211 and 231 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 153-173 of copending Application No. 10/729,056. Although the conflicting

Art Unit: 1617

claims are not identical, they are not patentably distinct from each other because the copending Application teaches an aspect of the claims in the instant application. For example, the method of claim 173 in the present application is similar to the method claimed in claim 153-173 utilizing same biological pathway comprising increasing the level of TGF-beta encompassing utilized same active agents. The copending application teaches the mechanisms of action or biological pathways presently claimed by Applicants and renders obvious the diseases claimed in the instant application.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 173-194, 196-203, 205-211 and 231 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 8 of U.S. Patent No. 6,410,587B1. Although the conflicting claims are not identical, they are not patentably distinct from each other because the patent disclose and teach an aspect of the claims in the present application. For example the method of claim 173 in the present application is similar to the method claims in 6,410,587B1. The independent claim 173 in instant application is to a method of treating cardiovascular or vascular indication characterized by a decreased lumen diameter comprising administering formula (I) encompassed by formula (VI) of the patent. However, the effect is similar as to inhibiting lipid accumulation therefore renders Applicants' claims obvious.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 173-181, 205-211 and 231 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sawada et al. (Pharmacometrics, 1992).

Sawada et al. teach the administration of toremifene citrate (NK622) in 0.1 mg/kg or more including 10mg/kg (cytostatic dose) to female rats showed decrease in total cholesterol in rats.

Sawada et al. do not teach a mammal at risk of or afflicted with cardiovascular or vascular indication (atherosclerosis) or mechanism of increasing the level of TGF-beta to decrease lesion formation or inhibition of lipid accumulation, and dosage formulation and the employment of analogs set forth in claim 176.

It would have been obvious to one of ordinary skill in the art to employ toremifene citrate (NK622) in 0.1 mg/kg or more including 10mg/kg (cytostatic dose) to a mammal at risk or afflicted with cardiovascular or vascular indication such as atherosclerosis. One

Art Unit: 1617

would have been motivated to employ toremifene citrate (NK622) in 0.1 mg/kg or more including 10mg/kg (cytostatic dose) to a mammal at risk or afflicted with cardiovascular or vascular indication such as atherosclerosis because Sawada et al. teach the administration of toremifene citrate (NK622) in 0.1 mg/kg or more including 10mg/kg (cytostatic dose) to female rats showed decrease in total cholesterol in rats. One would be further motivated to make such a modification in order to achieve an expected benefit of lowering total cholesterol level in a mammal suffering from atherosclerosis. The pharmaceutical forms, e.g., sustained release, immediate release etc; mode of administration, flavors, surfactant are all deemed obvious since they are all within the knowledge of the skilled pharmacologist and represent conventional formulations and modes of administration. Further, the reference discloses compounds which have a viable utility and are homologs, isomers or close structural analogs of the claimed compounds. The claimed compounds are so closely related structurally to the homologous; isomeric or analogous compounds of the reference as to be structurally obvious therefrom in the absence of any unobvious or unexpected properties especially since one of ordinary skill in the art would expect that compounds so closely related structurally would have the same or essentially the same properties. That applicant may have determined a mechanism by which the active ingredient gives increasing the level of TGF-beta to decrease lesion formation or inhibition of lipid accumulation does not alter the fact that the compound has been previously used to obtain the same pharmacological effects (lowering total cholesterol) which would result from the claimed method upon the administration of same active agent in a same amount to the mammal

Art Unit: 1617

in need thereof. An explanation of why that effect occurs does not make novel or even unobvious the treatment of the conditions encompassed by the claims.

Claims 182-194, 196-203, 205, 206 rejected under 35 U.S.C. 103(a) as being unpatentable over Warri (Dissertation Abstracts International, 1993).

Warri teaches the cellular and molecular mechanism of toremifene involving enhanced mRNA expression of TGF-beta in vitro and in vivo in breast cancer. Warri teaches the growth of breast cancer is inhibited by a new antiestrogen toremifene. (abstract).

Warri does not teach the vivo results involves a mammal suffering diabetes, retinopathy, the effective amounts, and the analogs set forth in claim 202.

It would have been obvious to one of ordinary skill in the art to employ toremifene in a mammal to increase the level of TGF-beta. One would have been motivated to make such a modification because increasing the level of TGF-beta in vivo by toremifene taught by Warri reduces breast cancer. One would have been motivated to increase the level of TGF-beta by employing toremifene in order to achieve an expected benefit of treating breast cancer in mammal in any population including the patients having any other multiple disorders including diabetes, retinopathy.

For these reasons the claimed subject matter is deemed to fail to patentably distinguish over the state of the art as represented by the cited references. The claims are therefore properly rejected under 35 U.S.C. 103.

None of the claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 5:30 am to 2 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Sreenivasan Padmanabhan
Supervisory Examiner
Art Unit 1617

Jmk
April 19, 2006